NTRK1 and central nervous system cancer: Novel biologic therapies under clinical evaluation for patients with high grade glioma include dendritic cell vaccination, tyrosine kinase receptor inhibitors, farnesyl transferase inhibitors, viral-based gene therapy, oncolytic viruses, vascular endothelial growth factor inhibitors and Epidermal growth factor-receptor inhibitors [25,26].